• Corpus ID: 10875022

Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.

  title={Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.},
  author={Norbert Brock and J. Pohl},
  journal={IARC scientific publications},
  • N. Brock, J. Pohl
  • Published 1986
  • Medicine, Biology
  • IARC scientific publications
Urotoxic side effects, particularly haemorrhagic cystitis, have been a limiting factor for the therapeutic use of the oxazaphosphorine cytostatics cyclophosphamide, ifosfamide and trofosfamide. The development of mesna (Uromitexan) has made it possible to carry out regional detoxification in the kidneys and the efferent urinary tract and thus to achieve clinically prophylaxis against the urotoxic side effects of oxazaphosphorines. In the body, mesna is rapidly converted to the biologically… 
Oxazaphosphorines: new therapeutic strategies for an old class of drugs
An increased knowledge of oxazaphosphorines' metabolism and toxicity may allow the development of new anticancer drugs combined with drug delivery systems to circumvent drug toxicity, providing increased tumoral specificity and greater anticancer activity.
Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro- and nephrotoxicities by modulating antioxidant status and pro-inflammatory cytokine levels
I. obscura can ameliorate CP-induced bladder and renal toxicities by modulating antioxidant status and proinflammatory cytokine levels, as evident from the decrease in BUN, serum creatinine levels as well as an increase in body weight.
Acacia senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity
GA, a potential protective agent, produced an almost complete reversal of NO induction, lipid peroxidation or cellular GSH bladder contents in the GA + CYCL-treated group, and bladder inflammation and edema were reduced and a remarkable recovery in their responsiveness to ACh.
Clinical Pharmacology of Cyclophosphamide and Ifosfamide
The oxazaphosphorine cyclophosphamide (CPA) and ifosfamide (IFO) are two commonly used DNA- alkylating agents in cancer chemotherapy and the pharmacokinetics and pharmacodynamics of the two important agents are highlighted.
Metabolism and Transport of Oxazaphosphorines and the Clinical Implications
This review highlights the metabolism and transport of these oxazaphosphorines (mainly CPA and IFO, as these two oxazphosphorine drugs are the most widely used alkylating agents) and the clinical implications.
Protective effects of Emblica officinalis Gaertn. in cyclophosphamide-treated mice
It is suggested that E. officinalis or its medicinal preparations may prove to be useful as a component of combination therapy in cancer patients under CP treatment regimen, and plant extract in particular was very effective in reducing CP-induced suppression of humoral immunity.
Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin
The potential for clinical translation of the cooperative interaction of palifosfamide-tris with doxorubicin by intravenous administration is supported by results from a recent randomized Phase-II study in unresectable or metastatic soft-tissue sarcoma.
Experiments on the Carcinogenic Potential of Antineoplastic Agents
This chapter will focus on some strategies to reduce the hazard of second cancer induction, as conducted at the Institute of Toxicology and Chemotherapy of the German Cancer Research Center during the last 15 years.
Chemical Profiling of Polyphenolics in Eucalyptus globulus and Evaluation of Its Hepato–Renal Protective Potential Against Cyclophosphamide Induced Toxicity in Mice
Results revealed the protective effects of EG against CP-induced hepato–renal toxicity and may be related to EG antioxidant, anti-inflammatory, and anti-apoptotic properties coupled with activation of Nrf2/HO-1 signaling.